Trivedi, Ashit
Mather, Omar
Vega, Silvia
Simiens, Mary Ann
Hellawell, Jennifer
Lee, Edward
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effect of Severe Renal Impairment on the Safety, Tolerability, and Pharmacokinetics of AMG 986
https://doi.org/10.1007/s40268-021-00380-1
Funding for this research was provided by:
amgen
Article History
Accepted: 21 December 2021
First Online: 29 January 2022
Declarations
:
: This study was funded by Amgen Inc.
: AT, OM, SV, MAS, JH, and EL are employees and shareholders of Amgen Inc.
: Qualified researchers may request data from Amgen clinical studies; complete details are available at ExternalRef removed.
: Not applicable.
: The study was conducted following ethical guidelines of the Declaration of Helsinki and Council for International Organizations of Medical Sciences, applicable Good Clinical Practice guidelines of the International Council for Harmonisation, and applicable local laws and regulations. Locally appointed ethics review boards (Aspire IRB [Santee, CA, US], Copernicus Group IRB [Cary, NC, US], and IntegReview IRB [Austin, TX, US]) approved the research protocol.
: Written informed consent was obtained from all participants.
: Not applicable.
: All authors provided substantial contributions to the conception or design of the study; or the acquisition, analysis, or interpretation of data for the study; and drafted the manuscript or revised it critically for important intellectual content; and gave final approval of the manuscript to be published.